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Abstract
Background: Divergently selected Lean and Fat mouse lines represent unique models for a polygenic form of
resistance and susceptibility to obesity development. Previous research on these lines focused mainly on obesity-
susceptible factors in the Fat line. This study aimed to examine the molecular basis of obesity-resistant mechanisms
in the Lean line by analyzing various fat depots and organs, the liver transcriptome of selected metabolic
pathways, plasma and lipid homeostasis and expression of selected skeletal muscle genes.
Results: Expression profiling using our custom Steroltalk v2 microarray demonstrated that Lean mice exhibit a
higher hepatic expression of cholesterol biosynthesis genes compared to the Fat line, although this was not
reflected in elevation of total plasma or liver cholesterol. However, FPLC analysis showed that protective HDL
cholesterol was elevated in Lean mice. A significant difference between the strains was also found in bile acid
metabolism. Lean mice had a higher expression of Cyp8b1, a regulatory enzyme of bile acid synthesis, and the
Abcb11 bile acid transporter gene responsible for export of acids to the bile. Additionally, a higher content of
blood circulating bile acids was observed in Lean mice. Elevated HDL and upregulation of some bile acids
synthesis and transport genes suggests enhanced reverse cholesterol transport in the Lean line - the flux of
cholesterol out of the body is higher which is compensated by upregulation of endogenous cholesterol
biosynthesis. Increased skeletal muscle Il6 and Dio2 mRNA levels as well as increased activity of muscle succinic
acid dehydrogenase (SDH) in the Lean mice demonstrates for the first time that changes in muscle energy
metabolism play important role in the Lean line phenotype determination and corroborate our previous findings
of increased physical activity and thermogenesis in this line. Finally, differential expression of Abcb11 and Dio2
identifies novel strong positional candidate genes as they map within the quantitative trait loci (QTL) regions
detected previously in crosses between the Lean and Fat mice.
Conclusion: We identified novel candidate molecular targets and metabolic changes which can at least in part
explain resistance to obesity development in the Lean line. The major difference between the Lean and Fat mice
was in increased liver cholesterol biosynthesis gene mRNA expression, bile acid metabolism and changes in
selected muscle genes’ expression in the Lean line. The liver Abcb11 and muscle Dio2 were identified as novel
positional candidate genes to explain part of the phenotypic difference between the Lean and Fat lines.
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The 20th century is marked by an explosive increase in
obesity and metabolic syndrome commencing in popu-
lations of the Western world in the 1960’sa n di s
becoming a significant burden also in developing
nations [1]. Metabolic syndrome encompasses a cluster
of deleterious metabolic events characterized by obe-
sity, hyperglycemia, insulin resistance, hypercholestero-
lemia, hypertriglyceridemia and hypertension.
Environmental determinants influencing the develop-
ment of the metabolic syndrome include low-cost
highly palatable foods and the increasing mechaniza-
tion of transport and manual tasks following the indus-
trial revolution. While the intake of calories gradually
declined over the past decades, physical inactivity and
its interaction with geneticp r e d i s p o s i t i o nt oo b e s i t y
seem to be an increasingly prevalent determinant of
metabolic syndrome development [2,3].
Previous research in the field of metabolic syndrome
and obesity primarily studied monogenic knockout
rodent models [4]. Although murine models with single-
gene mutations are useful to study the effects of a few
genes with major effect on human obesity, monogenic
defects account for only a minority of patients with
morbid obesity. In contrast, epidemic proportions of the
metabolic syndrome and obesity are ascribed to the
polygenic effects, where multiple genes interact with
many environmental factors over time [5,6]. Thus, single
gene animal models can not explain a large portion of
genetic variation that exists in the polygenic form mak-
ing polygenic obesity mouse models [7,8], such as the
lines used herein, a more suitable genetic resource.
Accordingly, we employed Lean and Fat mouse lines
developed from the same base population by long-term
(over 60 generations) divergent selection for low or high
body fat % [9]. These Fat and Lean mouse lines may
represent a unique model of the prevalent polygenic
form of human obesity and leanness. Because previous
research focused mainly on investigating obesity-sus-
ceptibility in the Fat line (e.g., [10-12]), we here aimed
to elucidate the molecular basis of obesity-resistance in
the Lean line.
We performed a thorough phenotypic characteriza-
tion of the Lean and Fat lines. In addition, a gene-
expression analysis was conducted on the liver tissue
using the Steroltalk v2 microarray that was previously
used to study hepatic lipid homeostasis [13-15]. This
custom microarray is designed for detailed studies of
genes from the cholesterol homeostasis and drug meta-
bolism networks, including bile acid metabolism, and
several genes from the fatty acid and glucose pathways
as well as related transporters for the aforementioned
processes.
The results of our study combined with previous find-
ings help to identify, at least in part, a molecular basis
for the contrasting phenotype between the Lean and Fat
mice and substantiate a hypothesis that differences in
metabolic interactions between skeletal muscle and liver
tissues play an important part in the phenotype diver-
gence between these lines. The Lean mouse line exhibits
characteristics that uncover some of the factors involved
in genetic predisposition for obesity-resistance that may
also be relevant for obesity and metabolic syndrome
basic and applied research in humans.
Methods
Animals and maintenance
Inbred lean (Lean) and fat (Fat) mouse lines used here
were developed by long-term (over 60 generations)
divergent selection for low or high body fat % [9,16].
Our previous genetic studies demonstrated that these
lines differ in large part due to cumulative action of
multiple quantitative trait loci (QTLs) of small to med-
ium sized effects, confirming that these lines may pre-
sent a valuable model of the polygenic form of leanness/
obesity [17-19].
Animals were weaned at 3 weeks of age and one pair
of males (usually brothers) was housed per cage. Cages
were randomly distributed on the rack in order to mini-
mize localized environmental effects and mice were
maintained at 21.5°C (± 0.5) with 12 h light/dark cycle.
Mice were fed maintenance chow diet (Altromin 1324,
Lage, Germany), containing: crude oil, 4%; crude pro-
tein, 19%; crude fibre, 6%; ash, 7%; moisture, 13.5%;
metabolizable energy, 11.9 MJ/kg where 24 %, 11 % and
65 % of calories from protein, fat and carbohydrates,
respectively. Body weights were recorded at 3, 6, 10 and
14 weeks of age. All procedures on animals were per-
formed according to local ethical and regulatory guide-
lines, which are all in compliance with the EU
regulations regarding research on experimental animals.
Phenotype measurements and analyses
At 14 weeks of age (± 3 days) a total of 43 Lean and 42
Fat males were sacrificed after four hour fast by decapi-
tation. Samples of blood, liver, entire left epididymal,
left abdominal (perirenal and retroperitoneal), left
femoral fat, mesenterial fat, heart and striated muscle
from regio cruris (m.gastrocnemius)a n dt h i g hm u s c l e
(m. quadriceps) were weighed, promptly frozen in liquid
nitrogen and stored at -80°C.
Blood was collected in Li-heparin tubes (Sarstedt, Ger-
many) and centrifuged within 3 h of collection at 3000
rpm/min, for 10 min at +4°C. Plasma samples of 10
Lean and 10 Fat mice were individually analyzed for
total plasma cholesterol, HDL-cholesterol, plasma
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cholesterol and triglyceride concentrations were deter-
mined by enzymatic assays adapted to microtiter plates
using commercially available reagents (BioMerieux,
Lyon, France). Plasma HDL-cholesterol levels were mea-
sured after precipitation of apolipoprotein (Apo) B-con-
taining lipoproteins with phosphotungstic acid/Mg
(Roche Diagnostics GmbH, Mannheim, Germany). Non-
HDL cholesterol was obtained by subtraction of HDL-
cholesterol values from total plasma cholesterol.
Plasma lipoproteins were separated by gel filtration
chromatography using a Superose 6 HR 10/30 column
(Pharmacia, Sweden). The gel was allowed to equilibrate
with 10 mM phosphate-buffered saline (PBS) containing
0.01% (wt/vol) EDTA and 0.01% (wt/vol) sodium azide.
Plasma was eluted with the buffer at room temperature
at a flow rate of 0.2 ml per minute. The effluents were
collected in 0.22 ml fractions. Cholesterol and triglycer-
ide concentrations were determined in the eluted frac-
tions as described above.
Cholesterol distribution among lipoproteins was
obtained by separation of the major lipoprotein classes
(VLDL, IDL+LDL, and HDL) by fast protein liquid chro-
matography (FPLC) carried out on 200 μlo fp l a s m a
sample for Fat and Lean line, according to procedure
previously detailed [12]. Cholesterol concentrations were
determined in the eluted fractions.
Analysis of hepatic lipids in individual samples of 10
Lean and 10 Fat mice was carried out using frozen liver
tissue (50 mg) which was homogenized in SET buffer
(1 mL ; sucrose 250 mM, EDTA 2 mM and Tris 10 mM),
followed by two freeze-thaw cycles and three passages
through a 27-gauge syringe needle and a final freeze-
thaw cycle to ensure complete cell lysis. Protein content
was determined with the BCA method and triglyceride
and cholesterol was measured as described above.
Differences between the lines in all measured phenoty-
pic parameters were tested by an unpaired Student t-test
on untransformed data as the data exhibited normal
distribution.
SDH activity of striated muscles
Oxidative capacity of the muscle fibres (mid-portion of
m. gastrocnemius) was determined by the mitochondrial
succinate dehydrogenase (SDH) assay as described pre-
viously [20]. Briefly, 10 μm thick cryostat sections were
incubated for 45 minutes at 37°C in a moisture chamber
with the medium composed of equal volumes of 0.2 M
phosphate buffer saline (pH 7.6), 0.2 M disodium succi-
nate and aqueous solution of nitro-BT (1 mg/ml). After
incubation the slides were washed in tap water, dehy-
drated and mounted with Synthetic Mountant (Shandon,
USA). SDH has an important role in metabolism of tri-
carbonic acids by the Krebs cycles. In the histochemical
reaction the enzyme takes over the hydrogen from diso-
dium succinate and transfers it to the tetrasolium salt
(NBT), which turns visible in the form of blue formazan
granules.
To analyze the SDH activity in muscle fibres a Nikon
Microphot FXA microscope (Nikon Instruments Europe
BV, Badhoevendorp, The Netherlands) and the Lucia-G
analyzing software (Laboratory Imaging, Prague, Czech
Republic) were used. In total 12 of each Lean and Fat
line mice were analyzed. 150 muscle fibres of each
mouse were measured by densitometry. Higher % densi-
tometry indicated higher transparency resulting from
lower SDH-enzyme activity.
RNA isolation
10 liver samples were individually homogenized for
10 s using an Ultra-Turrax T8 homogenizer (IKA
Labortechnik, Germany) and RNA extracted in
»batches« (a pair of Fat and Lean line samples simulta-
neously) using TRIzol reagent (TRIzol
® reagent, Invi-
trogen, Life technologies). RNA quality was evaluated
by ND-1000 spectrophotometer (Nanodrop Technolo-
gies, Wilmington, USA) and Agilent 2100 bioanalyzer.
According to the given RINs (RNA integrity number) a
pairwise comparison between Fat and Lean line RNA
samples was made in order to couple samples with least
quality divergence. RIN values of all samples ranged
from 7.5-8.5 suggesting low variability and high overall
quality. Maximal tolerated RNA quality divergence for a
pair of Lean and Fat-line samples co-hybridized on the
same microarray was ± 0.5 RIN.
Microarray experiment
The Steroltalk v2 cDNA microarray used here was a
next generation of the previously described Sterolgene
v0 array [14] with additional cDNA probes detecting a
total of 278 mouse genes from selected metabolic path-
ways relevant to obesity research. The design and pre-
paration of these additional probes was the same as
described [14]. The Steroltalk v2 cDNA microarray was
focused on targeted functional groups such as enzymes
from cholesterol biosynthesis (18/21 probes; coverage
85.7%), nuclear receptor families (45/49 probes; cover-
age 93.75%; http://www.nursa.org/) and members of the
cytochrome P450 (38/103 probes, coverage 36.9%) [14].
Additionally, key enzymes of glucose and fatty acid
metabolism; transporters of xenobiotics, cholesterol and
bile acids; and proteins involved in cholesterol plasma
transport, circadian rhythm, and selected cell signalling
pathways involved in the regulation of cholesterol
homeostasis were included. A full list of genes con-
tained on the custom Steroltalk v2 array along with
associated functional groups is provided in Additional
file 1.
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line animals were labelled using Cy3 and Cy5 dye. To
20 μg of Lean and Fat line total RNA sample, spike of con-
trol RNAs was added: 250 pg of Firefly Luciferase mRNA
(Promega, Madison, WI, USA) and 0.5 μL of either test or
reference spike mix from Lucidea Universal Scorecard kit
(Amersham Biosciences, GE Healthcare UK limited, Little
Chalfont, UK). mRNA was reverse transcribed to amino-
allyl cDNA using 2.5 μg of Oligo dT (Invitrogen, Carlsbad,
CA, USA), 400 U of SuperScript™ III Reverse Transcrip-
tase (Invitrogen, Carlsbad, CA, USA) and 1 μLo f1 0m M
amino-allyl dUTP (Sigma, St Louis, MI, USA) according
to the manufacturer’s protocol. Reactions were stopped
after 2 hours by addition of 10 μL of 0.5 M EDTA and of
1 M NaOH and were further incubated at 65°C for
15 min. 10 μL of 1 M HCl was added and cDNA was puri-
fied using MinElute PCR Purification Kit (Qiagen GmBH,
Hilden, D) according to the manufacturer’s protocol with
exception of using a phosphate buffer (5 mM KPO4 pH
8.5 in 80% ethanol) for the washing step and MilliQ water
for elution. Purified amino-allyl cDNA was dried and
resuspended in 4.5 μLo f0 . 2MN a 2CO3 (pH 9.0) and
4.5 μL of cyanin-3 or cyanin-5 dye in DMSO (Amersham
Biosciences, GE Healthcare UK limited, Little Chalfont,
UK). The labelling reaction was incubated at room tem-
perature for two hours, precipitated by addition of 35 μL
of 0.1 M Na acetate (pH 5.2) and purified reaction using a
MinElute PCR Purification Kit (Qiagen GmBH, Hilden, D)
were added. Labelled cDNA was eluted in water and 1 μL
was used for evaluation on ND-1000 spectrophotometer
(Nanodrop Technologies, Wilmington, Delaware, USA).
10 Lean and Fat line cDNA samples, respectively, were co-
hybridized in pairs and dye swaps were performed. Using
LifterSlip cover glasses (Erie Scientific Company, Ports-
mouth, NH, USA) samples were hybridized for 16 h at
65°C using buffers 3×SSC and 0.2% SDS in humidified
hybridization chambers (HybChambers, GeneMachines,
San Carlos, CA, USA). The slides were washed and
scanned as described [14].
Images were analyzed using Array-Pro Analyzer 4.5
(Media Cybernetics, Bethesda, MD, USA). Three arrays
did not pass quality control parameters (mainly too
high signal to noise ratios) and hence 17 arrays were
included in downstream statistical analyses. Data were
normalized using OWNormalize, a widget for explora-
tive normalization of focused microarrays, implemented
within Orange software [21]. Data were first filtered to
exclude spots of low quality and then normalized using
LOWESS fit to “spike in” control RNAs (Firefly lucifer-
ase and Lucidea Universal Scorecard) according to their
average intensity. The raw and normalized gene expres-
sion data of 17 arrays together with experimental infor-
mation are deposited in Gene Expression Omnibus
database (http://www.ncbi.nlm.nih.gov/geo/, accession
number GSE24967) in compliance with MIAME stan-
dards [22]. Differential expression was assessed using
Student’s t-test at probability of type I error a=0.05.
Expression of genes was considered on individual basis
and therefore no multiple testing correction has been
applied.
Quantitative reverse transcription polymerase chain
reaction (qRT-PCR)
A random selection of differentially expressed genes
from the microarray experiment and some genes not
represented on the array (for assaying in muscle tissue)
were assayed by the qRT-PCR to validate array results
(Table 1 Table 2, and Figure 1). The same liver RNAs
were used as originally in the array experiments. In ana-
lyses of muscle genes, 8 and 10 RNAs from the Lean
and Fat were used, respectively - again, using the same
animals as used in the array experiment. Briefly, 1 μgo f
total RNA was DNAse I (Sigma, St Louis, MI, USA)
treated, reverse-transcribed (SuperScript™ III, Invitro-
gen, USA) using random primers (Promega, USA) and
Platinum
® SYBR
® Green qRT-PCR SuperMix-UDG
(Invitrogen, Carlsbad, CA, USA) and analyzed on an
ABI PRISM 7900 HT (PE Applied Biosystems, Foster
Table 1 Primer sequences used in quantitative qRT-PCR analyses
Gene name Gene symbol Sense primer
(5’-3’)
Antisense primer
(5’-3’)
3-hydroxy-3-methylglutaryl-Coenzyme A reductase Hmgcr
1 cttgtggaatgccttgtgattg agccgaagcagcacatgat
Low density lipoprotein receptor Ldlr
1 aggctgtgggctccatagg tgcggtccagggtcatct
Insulin induced gene 1 Insig1
2 tcacagtgactgagcttcagca tcatcttcatcacacccaggac
Peroxisome proliferator activated receptor a Ppara
3 cctcttcccaaagctccttca cgtcggactcggtcttcttg
Deiodinase iodothyronine type II Dio2
4 Mm00515664_m1
Interleukin-6 Il6
4 Mm00446190_m1
Glucose-6 phosphatase G6Pc
4 Mm00839363_m1
18 S ribosomal RNA 18S
5 cgccgctagaggtgaaattc ttggcaaatgctttcgctc
b-actin Actb ccgtgaaaagatgacccagatc cacagcctggatggctacgt
1 Reference [41];
2 Reference [42];
3 Reference [43] ;
4 Assay-on-demand (Applied Biosystems)
5 Reference [44].
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cols. Internal controls were 18 S rRNA for liver and
Actb (beta-actin) for muscle. Relative transcript levels
were statistically analyzed using the comparative Ct
(cycle threshold) and -ΔΔCt values [23]. Single-factor
analysis of variance and a probability of type I error
a=0.05 was used to determine statistical significance in
SPSS 14.0 (SPSS Inc., Chicago, Illinois, USA). Primer
sequences are provided in Table 1.
Results
Lean mice exhibit a liver transcriptome profile suggesting
improved cholesterol homeostasis, bile acid, glucose and
lipoprotein metabolism
Analysis of Steroltalk v2 microarray data identified 38
differentially expressed genes (P < 0.05) that were
further separated into metabolic pathway groups such as
cholesterol biosynthesis pathway, bile and glucose meta-
bolism, drug metabolism and others (Table 3). Gene-
expression differences as well as their statistical signifi-
cances were confirmed by qRT-PCR (Figure 1). Expres-
sion of several genes involved in the cholesterol
biosynthesis pathway was found to be elevated in Lean
mice (Table 3), suggesting that liver cholesterol produc-
tion might also be elevated compared to the Fat mice.
In addition, the Insig1 gene, a potent regulator of cho-
lesterol biosynthesis transcription factors and a modula-
tor of HMG-CoA reductase protein ubiquitination, was
also expressed at a higher level in Lean mice (Table 3).
Transporter genes involved in the uptake of plasma
bile acids into hepatocytes such as Slco1a1, Slco1a4,
Slco1b2, Slc10a1, and the cholesterol efflux transporter
Abcg5 were down-regulated in Lean mice. However,
Abcb11, which controls bile acid excretion, was up-regu-
lated. Cyp8b1, a gene encoding a bile acid synthesis
enzyme, was also expressed at a higher level in Lean
mice (Table 3).
Gluconeogenesis genes G6Pc (glucose-6-phosphatase,
catalytic) and Pdhb (pyruvate dehydrogenase beta) were
markedly down-regulated in Lean mice supporting pre-
viously identified predisposition of Lean line to normogly-
cemia and resistance to diabetes development (Table 3).
The Ldlr, Lip1 and Adipor2 receptors were up-regu-
lated in livers of Lean mice suggesting that livers of
Lean mice have an increased ability to capture athero-
genic LDL-cholesterol as well as to respond to the
white adipose tissue derived hormone adiponectin. In
contrast, the transcription factor Ppara,i n v o l v e di nt r i -
glyceride homeostasis, was down-regulated in Lean mice
(Table 3).
Many of the cytochromes P450 functioning in drug
and steroid hormone metabolism were down-regulated
(Cyp2a5, Cyp2b10, Cyp2b9 and Cyp3a41)a l t h o u g ht w o
(Cyp2c69 and Cyp1a2)w e r eu p - r e g u l a t e d( T a b l e3 ) .
However, it is important to note that the cDNA probes
used on the microarrays do not enable efficient differen-
tiation between the aforementioned CYP members,
w h i c hs h a r ear e l a t i v e l yh i g hs e q u e n c eh o m o l o g y .F o r
example, probes for Cyp2b10 and Cyp2b9 cross-react
Table 2 Differential gene expression in skeletal muscle
between the Lean and Fat mice
SKELETAL MUSCLE
(gene name)
Gene
symbol
log2 ratio
(qRT-PCR) *
L:F**
Interleukin-6 Il6 0.71* ↑
Deiodinase iodothyronine type II Dio2 -0.5* ↓
*P < 0.05.
**Up arrow indicates increased mRNA expression in the Lean (L) line and
down arrow decreased expression in the Lean line compared to the Fat (F)
line.
*
*
*
* *
*
*
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Figure 1 Comparison of randomly selected genes in the
microarray experiment and by qRT-PCR method. Five genes
shown to be differentially expressed by the microarray analysis
(upper panel) were randomly selected for validation by qRT-PCR
(lower panel). All five genes also showed statistical significant
differences (*P < 0.05) between the Lean and Fat line by qRT-PCR as
well as the same direction of gene-expression differences
supporting the credibility of microarray experiment. Average log2
ratios +/- standard errors are displayed.
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true for the Cyp2c, Cyp3a and Cyp2a probes. Therefore,
to determine exactly which gene from the CYP2,3
families is differentially expressed in our lines, future
experiment based on allele-specific hybridization probes
or gene specific RT-PCR assays should be conducted.
Lean mice display an improved profile of adiposity,
plasma lipoproteins, plasma bile acids and liver
triglycerides parameters
Food intake analysis demonstrated statistically non-
significant differences b e t w e e nL e a na n dF a tm i c e
(data not shown) supporting previous findings that
Table 3 Differential expression between the Lean and Fat mice in liver genes
Gene name Gene Symbol GeneBank Code Log2 ratio* L:F**
Cholesterol metabolism
Mevalonate kinase Mvk NM_023556 0.11 ↑
NAD(P) dependent steroid dehydrogenase-like Nsdhl BC019945 0.15 ↑
Sterol-C5-desaturase (fungal ERG3, delta-5-desaturase) homolog (S. cerevisae) Sc5d BC024132 0.27 ↑
Mevalonate (diphospho) decarboxylase Mvd NM_138656 0.29 ↑
Lanosterol synthase Lss NM_146006 0.33 ↑
Farnesyl diphosphate synthetase Fdps NM_134469 0.41 ↑
Farnesyl diphosphate farnesyl transferase 1 Fdft1 NM_010191 0.44 ↑
Acyl-CoA synthetase short-chain family member 2 Acss2 NM_019811 0.36 ↑
Bile acid and glucose metabolism
Glucose-6-phosphatase, catalytic G6Pc NM_008061 -1.01 ↓
Pyruvate dehydrogenase (lipoamide) beta Pdhb NM_024221 -0.28 ↓
Solute carrier organic anion transporter family, member 1a4 Slco1a4 NM_030687 -0.71 ↓
Solute carrier organic anion transporter family, member 1a1 Slco1a1 AY195868 -0.49 ↓
Solute carrier organic anion transporter family, member 1b2 Slco1b2 NM_020495 -0.36 ↓
Solute carrier family 10 (sodium/bile acid cotransporter family), member 1 Slc10a1 BC094023 -0.13 ↓
ATP-binding cassette, sub-family G (WHITE), member 5 Abcg5 NM_031884 -0.15
ATP-binding cassette, sub-family B (MDR/TAP), member 11 Abcb11 NM_021022 0.65 ↑
Cytochrome P450, family 8, subfamily b, polypeptide 1 Cyp8b1 NM_010012 0.52 ↑
Drug metabolism
Cytochrome P450, family 2, subfamily a, polypeptide 5 Cyp2a5 BC011233 -0.52 ↓
Cytochrome P450, family 2, subfamily b, polypeptide 10 Cyp2b10 AK028103 -0.44 ↓
Cytochrome P450, family 2, subfamily b, polypeptide 9 Cyp2b9 NM_010000 -0.38 ↓
Cytochrome P450, family 2, subfamily b, polypeptide 9 Cyp2b9 NM_007813 -0.38 ↓
Cytochrome P450, family 3, subfamily a, polypeptide 41A Cyp3a41a NM_017396 -0.37 ↓
Cytochrome P450, family 2, subfamily c, polypeptide 69 Cyp2c69 NM_010004 0.34 ↑
Cytochrome P450, family 1, subfamily a, polypeptide 2 Cyp1a2 NM_009993 0.41 ↑
Others
Complement component 9 C9 BC011137 -1.37 ↓
Serum amyloid P-component Apcs BC061125 0.46 ↑
Complement component 4B (Childo blood group) C4b BC067409 1.55 ↑
C-reactive protein, pentraxin-related Crp NM_007768 0.25 ↑
Orosomucoid 1 Orm1 BC012725 -0.34 ↓
Hemopexin Hpxn BC019901 0.12 ↑
Nuclear receptor subfamily 5, group A, member 2 (LRH-1) Nr5a2 NM_030676 0.16 ↑
Acetyl-Coenzyme A acetyltransferase 2 Acat2 NM_009338 0.22 ↑
Apolipoprotein A-II Apoa2 BC031786 0.23 ↑
Lysosomal acid lipase A Lip1 NM_021460 0.23 ↑
Low density lipoprotein receptor Ldlr BC019207 0.27 ↑
Insulin induced gene 1 Insig1 NM_153526 0.33 ↑
Nitric oxide synthase 1, neuronal Nos1 BC066101 0.34 ↑
Adiponectin receptor 2 Adipor2 NM_197985 0.35 ↑
*Data represent log2 ratios of Lean (L) versus Fat (F) line (p < 0.05).
**Up arrow indicates increased mRNA expression of particular gene in the Lean (L) line and down arrow decreased expression in the Lean line.
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ence, consume equal amounts of food [24]. Lean line
males compared to the Fat males exhibited signifi-
cantly lower body fatness at 14-weeks of age across all
dissected fat depots (Table 4). The relative weight
(normalized to body weight) of abdominal, femoral,
epididymal and mesenterial fat of Lean mice was
approximately 5.4, 4.0, 7.0 and 3.5 fold lower com-
pared to Fat line males, respectively. On the contrary,
the relative heart weight was1 . 3 4f o l dh i g h e ri nL e a n
versus Fat mice.
Plasma was individually analyzed in Lean and Fat
males for total plasma cholesterol (Figure 2A) and
HDL/total plasma cholesterol ratio (Figure 2B).
Non-HDL-cholesterol was calculated by subtracting
total plasma cholesterol from HDL-cholesterol and the
ratio of non-HDL-cholesterol/total plasma cholesterol
was subsequently calculated (Figure 2C). The beneficial
Table 4 Weights of fat depots and heart normalized to
body weight in Lean and Fat mice
Parameter Lean mice* Fat mice* No. of individuals
BODY WEIGHT at
14 weeks
(g)
28.17 ± 1.15 41.76 ± 3.22* L = 23; F = 24
ABDOMINAL FAT
ratio (mg/g body wt) 1.86 ± 069 9.97 ± 1.08
a L = 43; F = 42
FEMORAL FAT
ratio (mg/g body wt) 4.43 ± 1.2 17.67 ± 2.32
a L = 43; F = 42
EPIDIDYMAL FAT
ratio (mg/g body wt) 3.34 ± 0.85 23.24 ± 3.12
a L = 43; F = 42
MESENTERIAL FAT
ratio (mg/g body wt) 6.43 ± 1.26 22.33 ± 3.87
a L = 18; F = 15
HEART
ratio (mg/g body wt) 6.13 ± 0.87 4.58 ± 0.69
a L = 43; F = 42
*Results are expressed as means ± S.D. Except for mesenterial fat and heart,
means were calculated based on weighed left-sided fat depot (L; Lean mice,
F; Fat mice,
a P < 0.001).
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Figure 2 Detailed plasma cholesterol analyses in the Lean and Fat mice. A. Total plasma cholesterol concentrations. Although cholesterol
biosynthesis genes showed increased expression in the liver of Lean mice (Table 3), total blood plasma cholesterol concentration was not
significantly different to the Fat mice. Average concentrations of total plasma cholesterol (mg/dl) standard errors are displayed. B. Ratio of HDL-
cholesterol to total plasma cholesterol. Beneficial HDL-cholesterol is significantly (*P < 0.05) increased in Lean mice. Average ratios and standard
errors are displayed. C. Ratio of nonHDL-cholesterol to total plasma cholesterol. nonHDL-cholesterol was a derived parameter obtained by
subtracting total plasma cholesterol from HDL-cholesterol. As HDL-cholesterol is markedly elevated in Lean mice (Figure 2B), consequently the
Lean mice have significantly (*P < 0.05) lower ratio of atherogenic nonHDL-cholesterol to total plasma cholesterol. Average ratios and standard
errors are displayed. D. FPLC analysis of total plasma lipoproteins. Cholesterol distribution among lipoproteins was obtained by separation of the
major lipoprotein classes (VLDL, IDL+LDL, and HDL) by fast protein liquid chromatography (FPLC). This analysis determined in the Lean line a
higher peak in the HDL fraction as well as a shift of HDL particles towards increased fraction elution number, suggesting that both the size and
concentration of plasma HDL lipoproteins are elevated in Lean mice.
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Page 7 of 12HDL-cholesterol was markedly elevated in Lean
mice (Figure 2B) and consequently the Lean mice
showed significantly lower ratios of atherogenic
non-HDL-cholesterol versus total plasma cholesterol
(Figure 2C). However, despite the higher expression
level of genes involved in cholesterol biosynthesis in the
Lean mice (Table 3), total plasma cholesterol concentra-
tion was not significantly different between the lines
(Figure 2A). A follow up FPLC plasma analysis deter-
mined that the Lean line had a higher peak in the HDL
fraction as well as a shift of the HDL curve suggesting
that both the size and concentration of plasma HDL
lipoproteins were elevated in Lean mice (Figure 2D).
Significantly higher concentrations of total plasma bile
acids were found in Lean mice (Figure 3) as well as
lower hepatic triglyceride levels (Figure 4A). However,
total liver cholesterol analysis resulted in statistically
non-significant differences (Figure 4B) suggesting that
this unlikely presents a driving effect.
Lean mice show increased skeletal muscle oxidative
capacity
Analysis of m. gastrocnemius SDH-activity determined
by histochemical reaction identified marked differences
in oxidative capacity of skeletal muscle fibres from Fat
versus Lean mice. Significantly higher levels of SDH
activity were detected in muscle fibres of Lean mice
(Figure 5, P < 0.001). Skeletal muscle interleukin 6 (Il6)
mRNA level, a potent indicator of muscle physical activ-
ity, was examined using qRT-PCR. Lean mice muscle
tissue displayed markedly elevated Il6 gene expression
level (Table 2). Furthermore, a significant down- regula-
tion of iodothyronine, type II deiodinase (Dio2)i nm.
gastrocnemius and m. quadriceps of Lean mice (Table 2)
was determined.
Discussion
The main objective of the present study was to identify
candidate genes and molecular mechanisms responsible
for obesity-resistance in the Lean line. Additionally, we
aimed to investigate metabolic parameters of skeletal
muscle and liver tissue and how they relate to blood
lipoproteins, triglycerides, bile acids and liver transcrip-
tome. Phenotypic characterization and search of differ-
entially expressed genes was also carried out to identify
novel positional candidate genes that map to the regions
of quantitative trait loci determined in previous crosses
between the Fat and Lean mice.
Non-atherogenic lipoprotein profile in Lean mice
Plasma and liver cholesterol concentrations are, under
balanced diet conditions, determined by the affluence
from hepatic de-novo cholesterol biosynthesis. Addition-
ally, excretion rate of cholesterol and bile acids also con-
tribute to inter-individual variation of total plasma and
liver cholesterol.
In the current experiment a large number of liver cho-
lesterol biosynthesis genes were upregulated in the Lean
line, but this was not reflected in an elevation of total
liver and plasma cholesterol. This inconsistency could be
explained in two ways: 1) either upregulation of choles-
terol biosynthesis genes was not sufficient to increase the
metabolic flow in cholesterol biosynthesis pathway that
would result in an increased level of de novo hepatic cho-
lesterol; 2) or that novel and excess hepatic cholesterol
was excreted from the liver or metabolized to bile acids.
Since we have not measured the metabolic rate of hepatic
cholesterol biosynthesis or determined protein levels, we
can not confirm yet that the increase in mRNA expres-
sion resulted in increased metabolic rate of cholesterol
biosynthesis. Regulation of the cholesterol synthesis
genes is under control of the SREBP signalling pathway
[25] and upregulation observed in the Lean line is prob-
ably a result of activation of the SREBP transcription fac-
tor cascade. This is supported by our finding that Insig-1
and Ldlr, both being SREBP target genes, were up-regu-
lated in the Lean mice. The hypothesis that cholesterol in
the Lean mice would be excreted from the liver or meta-
bolized to bile acids at an enhanced rate has limited sup-
portive results. Higher efflux of cholesterol from the liver
to bile is not likely since one of the genes involved in this
process, Abcg5, is downregulated in the Lean mice.
Increase in bile acid synthesis is plausible, since Cyp8b1
was up-regulated. However; Cyp7a1, a rate-limiting
enzyme of bile acid synthesis, was not changed (data
from RT-PCR not shown). Nevertheless, Cyp7a1 gene
exhibits large interindividual differences in the level of
expression and this hinders statistical significance. Also,
we found that the nuclear receptor subfamily 5, group A,
member 2 (Nr5a2, also known as LRH-1), a regulator of
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Figure 3 Plasma bile acid concentration in the Lean and Fat
mice. Significantly higher concentrations (*P < 0.001) of total
plasma bile acids were determined in the Lean mice. Average
concentrations of plasma bile acids (μmol/L) with standard errors
are displayed.
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Page 8 of 12bile acid synthesis genes, is upregulated in Lean mice. In
order to fully explain why up-regulation of cholesterol
pathway genes in the Lean line did not lead to increased
levels of total liver and plasma cholesterol, future detailed
studies should be focused on protein and metabolic level
of cholesterol management in Lean and Fat lines.
Although we did not find statistically significant differ-
ences in total liver and plasma cholesterol between the
lines, the Lean mice livers did contain significantly less tri-
glycerides per mg of liver tissue than the Fat mice - Lean
mice had only about 50% of Fat mice triglyceride content
(Figure 4). Abcb11, a gene overexpressed in the Lean line
liver, is known to enhance the rate of triglyceride excretion
from the liver [26,27]. Also, in a transgenic Abcb11 overex-
pression model [28], increased liver Abcb11 expression
showed ameliorating effects on hepatic steatosis by increas-
ing excretion of biliary phospholipids and cholesterol. It is
possible therefore that upregulation of Abcb11 in the Lean
mice might account for their diminished content of liver
triglycerides. Abcb11 is also a strong positional candidate
because it maps within a QTL Fob1 on chromosome 2,
detected in our previous cross between Lean and Fat mice
[17]. Also supportive is a study in humans detecting 30
mutations in the ABCB11 gene that were associated with
different clinical phenotypes and triglyceride measurements
[29]. Therefore, Abcb11 could be one of the potential cau-
sal allelic variants between the Lean and Fat mice, which
can aid in explaining a part of the phenotype divergence
between the strains. Elevated HDL and upregulation of
some bile acids synthesis and transport genes suggests
enhanced reverse cholesterol transport in the Lean line. As
the cholesterol excretion rate is higher, Lean line compen-
sates this by upregulating of endogenous cholesterol bio-
synthesis as demonstrated by the array experiment.
We established that Lean mice have significantly ele-
vated plasma HDL. Interestingly, results from a previous
study on humans imply that more exercise leads to
increased total HDL and the average size of HDL parti-
cles [30]. FPLC analysis of plasma revealed similar
observations - Lean mice have higher HDL plasma con-
centrations and also tend to have HDL particles of
increased size. Interpretation for improved HDL profile
in Lean mice can be further substantiated by genetic
studies on HDL metabolism, where several QTLs were
demonstrated to determine plasma HDL concentration,
some also mapping to QTL regions detected in Fat and
Lean mice [17,31]. It is therefore possible that some of
the obesity QTLs identified in our previous genetic
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Figure 4 Triglyceride and total cholesterol content in the livers of Lean and Fat mice. A. Hepatic trygliceride levels. The liver of Lean mice
contains significantly lower (*P < 0.05) amounts of triglycerides. Average values for mg of triglycerides per mg of liver proteins with standard
errors are displayed. B. Total hepatic cholesterol levels. Despite that cholesterol biosynthesis genes showed increased mRNA expression in the
liver of Lean mice (Table 3), total liver cholesterol does not differ significantly from the Fat line. Average values for mg of total cholesterol per
mg of liver proteins with standard errors are displayed.
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Figure 5 SDH-activity in m. gastrocnemius muscle tissue of the
Lean and Fat mice. Striated muscle from regio cruris (m.
gastrocnemius) was used to determine mitochondrial succinate
dehydrogenase (SDH) activity levels. 12 of each Lean and Fat line
mice were analysed and 150 muscle fibers per mouse were
measured for densitometry. This histochemical assay demonstrated
marked (*P < 0.001) increased level of SDH activity in muscle fibers
of Lean mice suggesting pronounced increase in oxidative
metabolism in this line. % densitometry with standard errors are
displayed - lower transparency of muscle histological sections in the
Lean mice resulted from higher SDH-enzyme activity which in turn
gave lower % densitometry readings in the Lean line.
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Page 9 of 12studies have pleiotropic effects affecting both body fat %
and HDL levels in our polygenic animal model [17-19].
The explanation for the observed higher concentration
of HDL and lower concentration of LDL-cholesterol in
Lean mice may therefore lie in allelic differences in
some of the HDL QTLs between the Fat and Lean mice.
Plasma bile acids and changes in skeletal muscle
metabolism
The bile acid pool in plasma is maintained by the enter-
ohepatic recirculation. The uptake of bile acids that
return to the liver after intestinal absorption is mainly
mediated by a family of SLCO transporters (Slco1a1,
Slco1a4 , Slco10a1) [27] whose expression can be modu-
lated by plasma bile acids and cytokines. In our Lean
mice down-regulation of genes encoding the aforemen-
tioned hepatic bile acid transporters along with signifi-
cantly elevated concentrations of plasma bile acids was
detected. Other studies have also demonstrated that bile
acids can down-regulate expression of Slco genes and
up-regulate Abcb11 [32], which is in agreement with our
results obtained in the Lean line. Additional support
comes from a study identifying significant dose-depen-
dent mRNA suppression of Slco1a1 (Oatp1)a n d
Slco1a4 (Oatp2) in mice treated with cytokine IL6 [33].
Detailed in-vitro and in-vivo studies defined IL6 as by
far the most pronounced transcriptional regulator of, for
example, Slco1a1, Slco1a4 and Abcb11 [33,34]. IL6, also
termed as »exercise factor«, is highly expressed in con-
tracting (exercising) skeletal muscle and is the most
highly secreted systemic muscle cytokine during exercise
[35]. The expression level of Il6 mRNA serves as a pre-
dictor of plasma IL6 protein [36]. In line with these
reports, our analysis demonstrates high levels of expres-
sion of skeletal muscle Il6 mRNA in Lean mice. This
increased Il6 expression in the Lean line could be a con-
sequence of increased physical activity of Lean mice
reported in our previous experiments [37]. Thus, rela-
tively high IL6 plasma levels in Lean mice might sup-
press the expression of the Slco family of genes
subsequently leading to the increase in plasma bile
acids. However, future studies are needed to confirm
that the muscle-derived cytokine IL6 in the Lean mice is
directly responsible for down-regulation of Slco genes
and increase in plasma bile acids.
Because Lean mice contain elevated levels of plasma
bile acids we sought to interpret other potential meta-
bolic actions involving bile acids. Elevated levels of
plasma bile acids were found to lead to endocrine actions
with consequent impact on whole body energy homeos-
tasis [38]. This effect is elicited through the increased
mRNA expression of type II iodothyronine deiodinase
(Dio2) which was exemplified in the mouse brown adi-
pose tissue and in human skeletal muscle myoblasts [38].
Dio2 expression was elevated in our Lean mice and also
maps close to the Fob2 QTL, previously identified as one
of four loci significantly contributing to the divergent
body fat % in our polygenic mouse model [17]. In
humans, polymorphisms at the Dio2 locus determines
susceptibility to hypertension and diabetes [39,40]. Given
the expression difference in the present study and its
location to previously mapped QTL in the same mice, it
is plausible that the Dio2 allelic variant also exists in this
animal model, and may consequently determine differen-
tial expression and downstream consequences on pheno-
type in the Lean line.
The overall results of our current study are in line
with our previous energy budget results which suggested
that Lean mice expend more energy on physical activity
[11] and our follow-up study demonstrating higher run-
ning wheel activity as well as higher exercise-indepen-
dent posture allocation to more energy demanding
positions (Non-Exercise Activity Thermogenesis;
NEAT–standing, fidgeting, etc.) in Lean mice [37].
Increased oxidative capacity of muscle determined in
the current study and resulting increased levels of Il6
expression may therefore indeed stem from higher phy-
sical and NEAT activities leading to downstream favour-
able effects on the liver transcriptome, cholesterol, bile
acid, glucose and lipoprotein homeostasis.
However, the identified differences in liver transcrip-
tome and other parameters and their associations with
muscle metabolism and physical activity can explain
o n l yap a r to fal a r g ep h e n o t y p i cd i v e r g e n c eb e t w e e n
the Lean and Fat line. In a polygenic model it is
expected that many alleles at different loci will contri-
bute cumulatively to obesity resistance in various com-
ponents of energy intake and energy expenditure. Since
we showed in this study that Lean mice have similar
food intake to the Fat line, we can exclude hyperphagia
or genetic differences in energy intake as a major com-
ponent for the phenotypic divergence between the lines.
However, we have already shown earlier that thermore-
gulation [11] may also be increased in the Lean line and
potential differences in resting metabolic rate can not be
excluded. Therefore, more comprehensive experiments
monitoring behavioural traits in combination with meta-
bolic changes to measure differences in fuel oxidation
will be needed to provide a better basis for future quan-
titative evaluations of energy expenditure components
and fuel utilisation. Our current study reveals several
candidate genes as well as important target tissues on
which to base new targeted hypotheses to be tested in
the future.
Conclusions
Polygenic mouse models of leanness/obesity used in our
study comprise complex obesity-resistant (Lean line)
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Page 10 of 12and obesity-susceptible (Fat line) gene networks. This
study was designed to help identify candidate genes and
reveal some metabolic mechanisms responsible for the
phenotypic difference between these lines. Results of
liver transcriptome analysis along with markers of oxida-
tive capacity (SDH enzyme activity, Il6 expression) in
skeletal muscle suggests of multiple tissue metabolic
interactions in the obesity resistant Lean line. Candidate
genes, particularly those mapping to previously detected
QTL regions (Abcb11 and Dio2) between Lean and Fat
mice, and new phenotypic parameters obtained in this
study will give us leads to identify novel genes underly-
ing this complex network. The results of the present
study combined with previous findings help to elucidate,
at least in part, a molecular basis for the contrasting
phenotype between the Lean and Fat mice and sub-
stantiate a hypothesis concerning metabolic interactions
between the physical activity, skeletal muscle and liver
tissue. We demonstrate that the Lean mouse line is a
potentially good model for identifying novel genes and
mechanisms in obesity resistance.
Additional material
Additional file 1: List of genes contained on the custom Steroltalk
v2 microarray prepared for this study.
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